Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 150


Enhanced genetic instability and dasatinib sensitivity in mammary tumor cells lacking NEDD9.

Singh MK, Izumchenko E, Klein-Szanto AJ, Egleston BL, Wolfson M, Golemis EA.

Cancer Res. 2010 Nov 1;70(21):8907-16. doi: 10.1158/0008-5472.CAN-10-0353. Epub 2010 Oct 12.


A requirement for Nedd9 in luminal progenitor cells prior to mammary tumorigenesis in MMTV-HER2/ErbB2 mice.

Little JL, Serzhanova V, Izumchenko E, Egleston BL, Parise E, Klein-Szanto AJ, Loudon G, Shubina M, Seo S, Kurokawa M, Ochs MF, Golemis EA.

Oncogene. 2014 Jan 23;33(4):411-20. doi: 10.1038/onc.2012.607. Epub 2013 Jan 14.


NEDD9 promotes oncogenic signaling in mammary tumor development.

Izumchenko E, Singh MK, Plotnikova OV, Tikhmyanova N, Little JL, Serebriiskii IG, Seo S, Kurokawa M, Egleston BL, Klein-Szanto A, Pugacheva EN, Hardy RR, Wolfson M, Connolly DC, Golemis EA.

Cancer Res. 2009 Sep 15;69(18):7198-206. doi: 10.1158/0008-5472.CAN-09-0795. Epub 2009 Sep 8.


Inhibition of Src phosphorylation alters metastatic potential of osteosarcoma in vitro but not in vivo.

Hingorani P, Zhang W, Gorlick R, Kolb EA.

Clin Cancer Res. 2009 May 15;15(10):3416-22. doi: 10.1158/1078-0432.CCR-08-1657. Epub 2009 May 15.


NEDD9 and BCAR1 negatively regulate E-cadherin membrane localization, and promote E-cadherin degradation.

Tikhmyanova N, Golemis EA.

PLoS One. 2011;6(7):e22102. doi: 10.1371/journal.pone.0022102. Epub 2011 Jul 12.


Sam68 haploinsufficiency delays onset of mammary tumorigenesis and metastasis.

Richard S, Vogel G, Huot ME, Guo T, Muller WJ, Lukong KE.

Oncogene. 2008 Jan 17;27(4):548-56. Epub 2007 Jul 9.


Adiponectin haploinsufficiency promotes mammary tumor development in MMTV-PyVT mice by modulation of phosphatase and tensin homolog activities.

Lam JB, Chow KH, Xu A, Lam KS, Liu J, Wong NS, Moon RT, Shepherd PR, Cooper GJ, Wang Y.

PLoS One. 2009;4(3):e4968. doi: 10.1371/journal.pone.0004968. Epub 2009 Mar 25. Erratum in: PLoS One. 2009;4(4). doi: 10.1371/annotation/14cb7d7e-a921-4ae6-a405-99c60656579f.


Src kinase determines the dynamic exchange of the docking protein NEDD9 (neural precursor cell expressed developmentally down-regulated gene 9) at focal adhesions.

Bradbury P, Bach CT, Paul A, O'Neill GM.

J Biol Chem. 2014 Sep 5;289(36):24792-800. doi: 10.1074/jbc.M113.544106. Epub 2014 Jul 24.


Mammary epithelial-specific disruption of focal adhesion kinase retards tumor formation and metastasis in a transgenic mouse model of human breast cancer.

Provenzano PP, Inman DR, Eliceiri KW, Beggs HE, Keely PJ.

Am J Pathol. 2008 Nov;173(5):1551-65. doi: 10.2353/ajpath.2008.080308. Epub 2008 Oct 9.


Overexpression of aurora kinase A in mouse mammary epithelium induces genetic instability preceding mammary tumor formation.

Wang X, Zhou YX, Qiao W, Tominaga Y, Ouchi M, Ouchi T, Deng CX.

Oncogene. 2006 Nov 16;25(54):7148-58. Epub 2006 May 22.


Dasatinib inhibits mammary tumour development in a genetically engineered mouse model.

Karim SA, Creedon H, Patel H, Carragher NO, Morton JP, Muller WJ, Evans TR, Gusterson B, Sansom OJ, Brunton VG.

J Pathol. 2013 Aug;230(4):430-40. doi: 10.1002/path.4202.


The anticancer effect of PQ1 in the MMTV-PyVT mouse model.

Shishido SN, Delahaye A, Beck A, Nguyen TA.

Int J Cancer. 2014 Mar 15;134(6):1474-83. doi: 10.1002/ijc.28461. Epub 2013 Sep 19.


Dual inhibition of SRC and Aurora kinases induces postmitotic attachment defects and cell death.

Ratushny V, Pathak HB, Beeharry N, Tikhmyanova N, Xiao F, Li T, Litwin S, Connolly DC, Yen TJ, Weiner LM, Godwin AK, Golemis EA.

Oncogene. 2012 Mar 8;31(10):1217-27. doi: 10.1038/onc.2011.314. Epub 2011 Jul 25.


Inhibition of cell growth and up-regulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the Src/Abl inhibitor dasatinib.

Wang L, Guo B, Wang R, Jiang Y, Qin S, Liang S, Zhao Y, Guo W, Li K, Fan X.

Clin Sci (Lond). 2012 Jan;122(1):13-24. doi: 10.1042/CS20110230.


SRC signaling is crucial in the growth of synovial sarcoma cells.

Michels S, Trautmann M, Sievers E, Kindler D, Huss S, Renner M, Friedrichs N, Kirfel J, Steiner S, Endl E, Wurst P, Heukamp L, Penzel R, Larsson O, Kawai A, Tanaka S, Sonobe H, Schirmacher P, Mechtersheimer G, Wardelmann E, B├╝ttner R, Hartmann W.

Cancer Res. 2013 Apr 15;73(8):2518-28. doi: 10.1158/0008-5472.CAN-12-3023. Epub 2013 Apr 11.


Mena deficiency delays tumor progression and decreases metastasis in polyoma middle-T transgenic mouse mammary tumors.

Roussos ET, Wang Y, Wyckoff JB, Sellers RS, Wang W, Li J, Pollard JW, Gertler FB, Condeelis JS.

Breast Cancer Res. 2010;12(6):R101. doi: 10.1186/bcr2784. Epub 2010 Nov 25.


Early vascular deficits are correlated with delayed mammary tumorigenesis in the MMTV-PyMT transgenic mouse following genetic ablation of the NG2 proteoglycan.

Gibby K, You WK, Kadoya K, Helgadottir H, Young LJ, Ellies LG, Chang Y, Cardiff RD, Stallcup WB.

Breast Cancer Res. 2012 Apr 24;14(2):R67.


Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases.

Liu Y, Karaca M, Zhang Z, Gioeli D, Earp HS, Whang YE.

Oncogene. 2010 Jun 3;29(22):3208-16. doi: 10.1038/onc.2010.103. Epub 2010 Apr 12.


Expression of a phosphorylated substrate domain of p130Cas promotes PyMT-induced c-Src-dependent murine breast cancer progression.

Zhao Y, Kumbrink J, Lin BT, Bouton AH, Yang S, Toselli PA, Kirsch KH.

Carcinogenesis. 2013 Dec;34(12):2880-90. doi: 10.1093/carcin/bgt238. Epub 2013 Jul 3.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk